Ginn Scott G.'s most recent trade in Amedisys Inc. was a trade of 2,327 Common Stock done at an average price of $98.0 . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.03 per share. | 26 Jun 2025 | 2,327 | 91,729 (0%) | 0% | 98.0 | 228,116 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.09 per share. | 20 Feb 2025 | 2,430 | 94,056 (0%) | 0% | 91.1 | 221,349 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2025 | 17,495 | 98,281 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.60 per share. | 16 Feb 2025 | 1,795 | 96,486 (0%) | 0% | 92.6 | 166,217 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.00 per share. | 26 Jun 2024 | 2,391 | 80,786 (0%) | 0% | 92 | 219,972 | Common Stock |
| Amedisys Inc. | Ginn Scott G. | EVP, CFO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 16,553 | 86,395 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.69 per share. | 16 Feb 2024 | 3,218 | 83,177 (0%) | 0% | 93.7 | 301,494 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 16,446 | 69,842 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 8,627 | 8,627 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 8,173 | 8,173 | - | - | Restricted Stock Unit (Performance-Based Vesting) | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,087 | 53,396 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.16 per share. | 20 Feb 2023 | 2,207 | 49,309 (0%) | 0% | 97.2 | 214,432 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP, CFO & Acting COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 23,109 | 51,516 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 6,119 | 6,119 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 5,236 | 5,236 | - | - | Restricted Stock Unit (Performance-Based Vesting) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 2,618 | 30,382 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.07 per share. | 17 Feb 2022 | 1,975 | 28,407 (0%) | 0% | 141.1 | 278,613 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 160.38 per share. | 18 Oct 2021 | 800 | 27,764 (0%) | 0% | 160.4 | 128,304 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 160.38 per share. | 18 Oct 2021 | 400 | 28,564 (0%) | 0% | 160.4 | 64,152 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.97 per share. | 19 Jul 2021 | 96 | 28,964 (0%) | 0% | 255.0 | 24,477 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.98 per share. | 19 Jul 2021 | 49 | 29,060 (0%) | 0% | 255.0 | 12,494 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 975 | 0 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 261.60 per share. | 28 May 2021 | 975 | 29,109 (0%) | 0% | 261.6 | 255,060 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 28 May 2021 | 975 | 30,084 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 283.33 per share. | 30 Apr 2021 | 975 | 29,109 (0%) | 0% | 283.3 | 276,247 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 975 | 975 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 30 Apr 2021 | 975 | 30,084 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 260.40 per share. | 31 Mar 2021 | 975 | 29,109 (0%) | 0% | 260.4 | 253,890 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 31 Mar 2021 | 975 | 30,084 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 975 | 1,950 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 264.15 per share. | 26 Feb 2021 | 975 | 29,109 (0%) | 0% | 264.1 | 257,546 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2021 | 975 | 2,925 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 26 Feb 2021 | 975 | 30,084 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.48 per share. | 20 Feb 2021 | 885 | 29,109 (0%) | 0% | 292.5 | 258,845 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.48 per share. | 20 Feb 2021 | 222 | 30,137 (0%) | 0% | 292.5 | 64,931 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.48 per share. | 20 Feb 2021 | 143 | 29,994 (0%) | 0% | 292.5 | 41,825 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 6,776 | 30,359 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 5,030 | 22,879 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 3,200 | 3,200 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 2,541 | 2,541 | - | - | Restricted Stock Unit (Performance-Based Vesting) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 2,515 | 0 | - | - | Restricted Stock Unit (Performance-Based Vesting) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 1,271 | 23,583 (0%) | 0% | 0 | Common Stock | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.20 per share. | 17 Feb 2021 | 567 | 22,312 (0%) | 0% | 295.2 | 167,378 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 975 | 3,900 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 286.87 per share. | 29 Jan 2021 | 975 | 17,849 (0%) | 0% | 286.9 | 279,698 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 29 Jan 2021 | 975 | 18,824 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 241.62 per share. | 30 Nov 2020 | 975 | 17,849 (0%) | 0% | 241.6 | 235,580 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 975 | 225 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 30 Nov 2020 | 975 | 18,824 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 250.00 per share. | 30 Oct 2020 | 975 | 17,849 (0%) | 0% | 250 | 243,750 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 30 Oct 2020 | 675 | 18,824 (0%) | 0% | 27.3 | 18,461 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 675 | 1,200 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 300 | 0 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 30 Oct 2020 | 300 | 18,149 (0%) | 0% | 27.4 | 8,205 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.67 per share. | 18 Oct 2020 | 800 | 17,849 (0%) | 0% | 251.7 | 201,336 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.67 per share. | 18 Oct 2020 | 400 | 18,649 (0%) | 0% | 251.7 | 100,668 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 230.79 per share. | 30 Sep 2020 | 975 | 19,049 (0%) | 0% | 230.8 | 225,020 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 30 Sep 2020 | 975 | 20,024 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2020 | 975 | 300 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 236.44 per share. | 04 Sep 2020 | 975 | 19,049 (0%) | 0% | 236.4 | 230,529 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 975 | 1,275 | - | - | Stock Option (Right to Buy) | |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 04 Sep 2020 | 975 | 20,024 (0%) | 0% | 27.3 | 26,666 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.10 per share. | 19 Jul 2020 | 96 | 19,049 (0%) | 0% | 216.1 | 20,746 | Common Stock |
| Amedisys Inc. | Scott G. Ginn | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.10 per share. | 19 Jul 2020 | 49 | 19,145 (0%) | 0% | 216.1 | 10,589 | Common Stock |